Welcome to our dedicated page for Inspiremd news (Ticker: NSPR), a resource for investors and traders seeking the latest updates and insights on Inspiremd stock.
InspireMD Inc. (NSPR) is a medical device company pioneering MicroNet stent technology for stroke prevention through advanced carotid artery treatments. This page serves as the definitive source for verified corporate announcements, clinical developments, and strategic updates.
Investors and medical professionals will discover timely updates including FDA regulatory progress, international clinical trial results, product launch details, and partnership announcements. All content undergoes rigorous verification to ensure accuracy and relevance to stakeholder decision-making.
The resource features critical developments in vascular intervention technology, including innovations in embolic protection systems and expansion into new global markets. Users can track the company's progress through major clinical study publications and regulatory milestone achievements.
Bookmark this page for structured access to InspireMD's latest verified news. Check regularly for updates on carotid stenting advancements, financial disclosures, and evidence-based medical device innovations shaping stroke prevention care.
InspireMD (Nasdaq: NSPR) welcomed publication of the CREST-2 trial in the New England Journal of Medicine on Nov 24, 2025, and presentation at SVIN and VEITH on Nov 21, 2025. CREST-2 found that adding carotid artery stenting (CAS) to medical therapy in patients with high-grade asymptomatic carotid stenosis significantly reduced the composite risk of perioperative stroke or death or ipsilateral stroke through 4 years versus intensive medical therapy alone.
The trial reported that carotid endarterectomy (CEA) did not provide a significant benefit vs medical therapy in a separate arm. InspireMD highlighted its CGuard platform, citing a 1.93% major adverse event rate through 12 months in its C-GUARDIANS trial and >b>65,000 global implants as supporting evidence.
InspireMD (Nasdaq: NSPR) announced inducement grants approved November 20, 2025, awarding a total of 122,054 restricted shares to eight new non-executive employees under the company’s 2024 Inducement Plan.
The grants were made outside the 2021 Equity Incentive Plan as permitted by Nasdaq Listing Rule 5635(c)(4) and vest over three years: one-third on the first anniversary and two equal installments on the second and third anniversaries, subject to continued employment.
InspireMD (Nasdaq: NSPR) will participate in a fireside discussion at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 12:30 PM ET. The company, developer of the CGuard Prime carotid stent system, said a live audio webcast and a replay will be available on its Investor Calendar page. Investors can access the event via the provided webcast link and listen live or via the replay on the company website.
InspireMD (Nasdaq: NSPR) reported third quarter 2025 results and operational milestones on November 4, 2025. Total revenue rose 39% to $2.5M versus prior year, with U.S. revenue $497,000 and international $2.0M. The company initiated the U.S. commercial launch of CGuard Prime, recording over 100 U.S. procedures in leading hospitals. Gross profit was $864,000. Operating expenses increased to $13.9M (up 57%) driven by U.S. commercial hires and U.S. headquarters costs. Net loss was $12.7M, $0.17 per share versus $7.9M, $0.16 a year earlier. Cash and marketable securities totaled $63.4M, supported by $58M in gross proceeds raised in July. Management hosted a conference call on November 4, 2025 to discuss results.
InspireMD (Nasdaq: NSPR) appointed Peter A. Soukas, M.D. as Chief Medical Officer effective Nov 3, 2025 to advance clinical and medical strategy around its CGuard Prime carotid stent system.
Dr. Soukas will help support the planned U.S. launch, maintain his clinical practice, and bring academic and trial experience as Director of Vascular Medicine at The Miriam Hospital and Associate Professor at Brown University.
InspireMD (Nasdaq: NSPR) announced it will release its third quarter 2025 financial results on Tuesday, November 4, 2025.
The company will host a conference call and webcast on November 4, 2025 at 8:30 a.m. Eastern Time to review results and recent highlights. Domestic callers may dial 1-800-579-2543; international callers may dial 1-785-424-1789. Investors can join the live webinar via InspireMD’s website or the provided webcast registration link. A replay will be available shortly after the call and archived on the company website.
InspireMD (Nasdaq: NSPR) announced that its Compensation Committee approved inducement grants of 40,513 restricted shares to three new non-executive employees, granted outside the 2021 Equity Incentive Plan under Nasdaq Listing Rule 5635(c)(4).
The grants were made under InspireMD's 2024 Inducement Plan with a grant date of October 7, 2025. The restricted stock vests over three years: one-third on the first anniversary and the remainder in two equal installments on the second and third anniversaries, subject to continued employment.
InspireMD (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system, has announced the approval of inducement grants for five new non-executive employees. The Compensation Committee approved a total of 88,324 shares of restricted stock under the company's 2024 Inducement Plan.
The grants, made outside the company's 2021 Equity Incentive Plan, have a grant date of September 24, 2025. The restricted stock follows a three-year vesting schedule, with one-third vesting on the first anniversary and the remaining portions vesting equally on the second and third anniversaries, contingent on continued employment.
InspireMD (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system, has appointed Dan Dearen to its Board of Directors. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors.
Dearen's notable achievements include serving as President, co-Founder, and CFO of Axonics, Inc., which was acquired by Boston Scientific for $3.7 billion in November 2024. He also held key positions at Vessix Vascular (acquired by Boston Scientific for $425 million) and currently serves on the boards of JenaValve Technology and BetaBionics.
This appointment comes at a strategic time as InspireMD continues its U.S. commercial launch of CGuard Prime, following FDA approval.
InspireMD (NASDAQ:NSPR), the developer of the CGuard® Prime carotid stent system for stroke prevention, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10th at 10:00am ET.
Investors can access both the live audio webcast and replay of the presentation through the company's website investor calendar section at inspiremd.com/investors/investor-calendar/.
FAQ
What is the current stock price of Inspiremd (NSPR)?
What is the market cap of Inspiremd (NSPR)?
